APP下载

蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者的肝功能及肝纤维化的影响

2020-12-23王洁冰唐平阳徐会选

中国医药导报 2020年28期
关键词:肝功能临床疗效

王洁冰 唐平阳 徐会选

[摘要] 目的 探究蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者肝功能及肝纤维化的影响。 方法 选取2015年5月—2018年3月于河北省沧州市传染病医院收治的患者90例,按照随機数字表法分为对照组和观察组,各45例。对照组给予替诺福韦治疗,观察组给予蚁利肝胶囊联合替诺福韦治疗,比较两组临床疗效、实验室检查指标。结果 观察组的临床总有效率高于对照组,差异有统计学意义(P < 0.05)。两组治疗后血清总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平均低于治疗前,凝血酶原时间(PT)短于治疗前,且观察组TBIL、ALT、AST水平均低于对照组,PT短于对照组(P < 0.05)。两组治疗后透明质酸酶、血层粘连蛋白、Ⅳ型胶原、Ⅲ型前胶原水平均低于治疗前,且观察组低于对照组(P < 0.05)。观察组治疗23、46周的HBV-DNA转阴率均高于对照组,差异有统计学意义(P < 0.05)。 结论 蚁利肝胶囊联合替诺福韦对乙肝肝硬化患者的临床疗效显著,可保护肝细胞活性,显著改善患者肝脏功能,减轻肝脏纤维化,提高患者生活质量,值得临床推广应用。

[关键词] 蚁利肝胶囊;乙肝肝硬化;肝功能;肝纤维化;临床疗效

[中图分类号] R575          [文献标识码] A          [文章编号] 1673-7210(2020)10(a)-0147-04

Effect of Yiligan Capsules combined with Tenofovir on liver function and liver fibrosis in patients with hepatitis B cirrhosis

WANG Jiebing   TANG Pingyang   XU Huixuan

Department of Hepatology, Cangzhou Infectious Disease Hospital, Hebei Province, Cangzhou   061000, China

[Abstract] Objective To explore the effect of Yiligan Capsules combined with Tenofovir on liver function and liver fibrosis in patients with hepatitis B cirrhosis. Methods Ninety patients from May 2015 to March 2018 in Cangzhou Infectious Disease Hospital of Hebei Province were selected and divided into control group and observation group according to random number table method, 45 cases in each group. Control group was treated with Tenofovir, and observation group was given Yiligan Capsules combined with Tenofovir. Clinical efficacy and laboratory examination indexes of two groups were compared. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). After treatment, serum total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels of two groups were lower than those before treatment, prothrombin time (PT) of two groups was shorter than that before treatment, and the levels of TBil, ALT and AST in observation group were lower than those in control group, and PT in observation group was shorter than that in control group (P < 0.05). After treatment, the levels of hyaluronidase, blood laminin, type Ⅳ collagen and type Ⅲ procollagen in two groups were lower than those before treatment, and those in observation group were lower than those in control group (P < 0.05). The negative conversion rate of HBV-DNA in observation group was higher than that in control group at 23 and 46 weeks of treatment, and the differences were statistically significant (P < 0.05). Conclusion Yiligan Capsules combined with Tenofovir has significant clinical effect on patients with hepatitis B cirrhosis, it can protect the activity of liver cells, significantly improve the liver function, reduce liver fibrosis and improve the quality of life of patients, which is worthy of clinical application.

[Key words] Yiligan Capsules; Hepatitis B cirrhosis; Liver function; Liver fibrosis; Clinical effect

肝硬化為临床常见、多发又严重的慢性肝损伤疾病,是由多种损伤因素长期作用于肝脏所致[1]。在中国,其发生与乙肝病毒(HBV)感染密切相关[2],据统计,我国HBV感染者约9000万,其中肝硬化的发生率高达40%[3],并且该比例在持续攀升[4]。HBV感染后不断在肝细胞内复制,初期可无明显临床表现,故极易被忽视[5],日久肝细胞发生广泛性坏死,免疫功能严重受损,肝脏纤维组织增生,甚则导致肝癌、肝性脑病等并发症及其他系统疾病的发生[6],严重威胁患者的生命健康安全。目前,现代医学多以抗病毒及相应对症治疗为主,但长期应用不良反应、毒副作用明显,患者依从性差,且治疗过程中耐药性的出现成为了治疗本病的难题。随着祖国医学对本病的不断深入研究,加之自身独具的优势与特色,在抗纤维化、保护肝功等方面发挥了积极作用[7],并指出该病的发生与肝、脾、肾关系密切,以辨证论治为指导原则,灵活用药,收获效果显著。……

登录APP查看全文

猜你喜欢

肝功能临床疗效
重视肝功能正常的慢性HBV感染者
肝功能报告单解读
探讨氯吡格雷预防冠心病介入治疗心血管的临床疗效
131碘治疗甲亢患者的后期随访效果分析
枸橼酸咖啡因治疗早产儿原发性呼吸暂停临床分析
微创手术治疗胃溃疡42例临床分析
研究腹腔镜在早期卵巢癌分期手术中的临床应用
早期应用前列地尔治疗急性脑梗死临床疗效观察
慢性乙肝患者HBV-DNA、HBeAg及肝功能的关系分析
注射用头孢呋辛钠静脉滴注致肝功能损害1例